A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB

Mucopolysaccharidosis type IVB (MPSIVB) is a lysosomal storage disorder caused by (3-galactosidase ((3 (3-GAL) deficiency fi ciency characterized by severe skeletal and neurological alterations without approved treatments. To develop hematopoietic stem progenitor cell (HSPC) gene therapy (GT) for MPSIVB, we designed lentiviral vectors (LVs) encoding human (3-GAL to achieve supraphysiological release of the therapeutic enzyme in human HSPCs and metabolic correction of diseased cells. Transduced HSPCs displayed proper colony formation, proliferation, and differentiation capacity, but their progeny failed to release the enzyme at supraphysiological levels. Therefore, we tested alternative LVs to overexpress an enhanced (3-GAL deriving from murine (LV-enhGLB1) and human selectively mutated GLB1 sequences (LV-mutGLB1). Only human HSPCs transduced with LVenhGLB1 overexpressed (3-GAL in vitro and in vivo without evidence of overexpression-related toxicity. Their hematopoietic progeny efficiently fi ciently released (3-GAL, allowing the cross-correction of defective cells, including skeletal cells. We found that the low levels of human GLB1 mRNA in human hematopoietic cells and the improved stability of the enhanced (3-GAL contribute to the increased efficacy fi cacy of LV-enhGLB1. Importantly, the enhanced (3-GAL enzyme showed physiological lysosomal trafficking fi cking in human cells and was not associated with increased immunogenicity in vitro. These results support the use of LVenhGLB1 for further HSPC-GT development and future clinical translation to treat MPSIVB multisystem disease.